As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Continued Unmet Needs and Track New Launches
June 26, 2024 04:00 ET
|
Spherix Global Insights
EXTON, PA, June 26, 2024 (GLOBE NEWSWIRE) -- Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disorder in which red blood cells prematurely break apart, a process known as hemolysis....
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
June 13, 2024 11:39 ET
|
Spherix Global Insights
EXTON, PA, June 13, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare kidney disease that presents significant challenges for both patients and nephrologists. Currently, there are...
Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
May 29, 2024 13:46 ET
|
Lynch Carpenter
PITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) -- Cencora, Inc. recently announced that it suffered from a cybersecurity attack that occurred in February of 2024, which impacted the personal information...
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market
April 16, 2024 14:06 ET
|
Spherix Global Insights
EXTON, PA, April 16, 2024 (GLOBE NEWSWIRE) -- In October of 2023, the US FDA approved Novartis’ intravenous (IV) formulation of Cosentyx (secukinumab) for the treatment of psoriatic arthritis (PsA),...
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
March 14, 2024 15:11 ET
|
Spherix Global Insights
EXTON, PA, March 14, 2024 (GLOBE NEWSWIRE) -- The past several years have brought a transformative shift to the IgA nephropathy (IgAN) treatment landscape, including the introduction of two new...
Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for Significant Future Adoption at the Expense of AbbVie's Humira
January 10, 2024 15:58 ET
|
Spherix Global Insights
Exton, Pennsylvania, Jan. 10, 2024 (GLOBE NEWSWIRE) -- In late October 2023, the FDA granted approval to Novartis' Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as...
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
December 21, 2023 07:30 ET
|
Arch Biopartners
TORONTO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval in Turkey from the Kocaeli...
Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, Novartis, Seagen, Pfizer, Celgene, and AstraZeneca
December 19, 2023 10:00 ET
|
Related Sciences
Former CEOs and executives from Genentech, Novartis, Seagen, Pfizer, and Celgene join drug AI/ML drug discovery firm Related Sciences as senior advisors.
US Neurologists Emphasize Tremendous Unmet Treatment Need in Parkinson's Disease, According to Spherix Global Insights
November 07, 2023 10:41 ET
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Parkinson's disease (PD) is the second-most prevalent neurodegenerative disorder following Alzheimer's disease, affecting an estimated one...
Fairway Consulting Group Appoints Matthew Perry as Vice President of Executive Search
October 19, 2023 08:45 ET
|
Fairway Consulting Group
Fairway Consulting Group Appoints Matthew Perry as Vice President of Executive Search